Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026)
Climb Bio's (CLYM) quarterly Depreciation & Amortization (CF) came in at $38000.0 in Q1 2026, up 26.67% on a QoQ basis from $30000.0 in Q4 2025.
Powered by 
Analysis
Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends
Climb Bio (CLYM) has 2 years of Depreciation & Amortization (CF) data on file, last reported at $38000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $38000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135000.0 (changed N/A YoY) and the FY2025 annual result came in at $97000.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) climbed to $38000.0 in Q1 2026, from $30000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $38000.0 in Q2 2025 to a low of $29000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Climb Bio | 1.17 Bn | 1.17 Bn | - | 33,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33,000.00 |
| Mar 31, 2026 | 38,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 38,000.00 |